AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16729400 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside
Number of subjects: 379
Study 16729400 — intervention group
Group type: EXPERIMENTAL
Intervention: Both nitroglycerin and nitroprusside
Number of subjects: 379
Study 14765636 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser (250 mW for 10 seconds)
Number of subjects: 5
Study 14765636 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fluoride (0.5% fluoride ion) followed by argon laser
Number of subjects: 5
Study 14765636 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 5
Study 11552048 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA, 50 mg/day)
Number of subjects: 96
Study 11552048 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (sustained-release preparation 400 mg/day)
Number of subjects: 96
Study 11552048 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ASA and dipyridamole
Number of subjects: 96
Study 11552048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 9245879 — intervention group
Group type: EXPERIMENTAL
Intervention: High resolution ultrasound
Number of subjects: 84
Study 9245879 — intervention group
Group type: COMPARATOR
Intervention: Mammography
Number of subjects: 84
Study 9245879 — intervention group
Group type: COMPARATOR
Intervention: Histology
Number of subjects: 84
Study 8471228 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous rHuEPO (IV)
Number of subjects: 50
Study 8471228 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous rHuEPO (SC)
Number of subjects: 50
Study 8471228 — intervention group
Group type: COMPARATOR
Intervention: Nandrolone decanoate (ND)
Number of subjects: 50
Study 3612782 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous coronary heart disease (CHD) risk-factor intervention program (SI group)
Number of subjects: 220
Study 3612782 — intervention group
Group type: COMPARATOR
Intervention: No intervention (UC group)
Number of subjects: 220
Study 29910056 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic mesenchymal stromal cells (allo‐MSCs) via 20 transendocardial injections
Number of subjects: 36
Study 29910056 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo) via 20 transendocardial injections
Number of subjects: 36
Study 26831919 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD/CAM zirconia abutments with cemented lithium disilicate crowns
Number of subjects: 110
Study 24733462 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-791325 (100, 300, 600, or 900 mg)
Number of subjects: 24
Study 24733462 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-791325 (900 mg)
Number of subjects: 24
Study 24733462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 22971555 — intervention group
Group type: EXPERIMENTAL
Intervention: F+R (feedback of activity counts + reinforcement for physical activity by providing access to television)
Number of subjects: 61
Study 22971555 — intervention group
Group type: EXPERIMENTAL
Intervention: F+R
Number of subjects: 61
Study 22971555 — intervention group
Group type: COMPARATOR
Intervention: Feedback
Number of subjects: 61
Study 22971555 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 61
Study 20466313 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs published in the Journal of Dental Research (high impact factor journal)
Number of subjects: 163
Study 20466313 — intervention group
Group type: COMPARATOR
Intervention: RCTs published in other journals (European Journal of Oral Sciences, Journal of Dentistry, Clinical Oral Investigations)
Number of subjects: 163
Study 17900584 — intervention group
Group type: EXPERIMENTAL
Intervention: Infracoccygeal sacropexy (IS)
Number of subjects: 49
Study 17900584 — intervention group
Group type: COMPARATOR
Intervention: Sacrospinous suspension (SS)
Number of subjects: 49
Study 15365074 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan plus gemcitabine (IRINOGEM)
Number of subjects: 180
Study 15365074 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine monotherapy (GEM)
Number of subjects: 180
Study 11384790 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop strategies to enhance adherence and retention
Number of subjects: 0
Study 9648993 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ulcerative colitis (n=61)
Number of subjects: 339
Study 9648993 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Crohn's disease (n=76)
Number of subjects: 339
Study 9648993 — intervention group
Group type: COMPARATOR
Intervention: Relatives of patients with ulcerative colitis (n=101)
Number of subjects: 339
Study 9648993 — intervention group
Group type: COMPARATOR
Intervention: Relatives of patients with Crohn's disease (n=105)
Number of subjects: 339
Study 9648993 — intervention group
Group type: COMPARATOR
Intervention: Healthy unrelated controls (n=56)
Number of subjects: 339
Study 7719261 — intervention group
Group type: EXPERIMENTAL
Intervention: Berodual
Number of subjects: 59
Study 7719261 — intervention group
Group type: COMPARATOR
Intervention: Fenoterol
Number of subjects: 59
Study 7719261 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium Bromide
Number of subjects: 59
Study 2680684 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-sec continuous rattle sound
Number of subjects: 64
Study 2680684 — intervention group
Group type: COMPARATOR
Intervention: 14-msec rattle sound
Number of subjects: 64
Study 2680684 — intervention group
Group type: COMPARATOR
Intervention: 500-msec rattle sound
Number of subjects: 64
Study 2680684 — intervention group
Group type: COMPARATOR
Intervention: 90 dB, 14-msec rattle sound
Number of subjects: 64
Study 2680684 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-sec sound at 70 dB
Number of subjects: 64
Study 2680684 — intervention group
Group type: EXPERIMENTAL
Intervention: Trains of repeated 14-msec rattle sounds (2/sec, 1.3/sec, and 1/sec) lasting 10 sec
Number of subjects: 64
Study 2680684 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-sec continuous rattle sound
Number of subjects: 64
Study 2680684 — intervention group
Group type: COMPARATOR
Intervention: Slowly repeating sounds
Number of subjects: 64
Study 920496 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide treatment for alcohol withdrawal
Number of subjects: 18
Study 920496 — intervention group
Group type: COMPARATOR
Intervention: Low dose ethanol treatment for alcohol withdrawal
Number of subjects: 18
Study 920496 — intervention group
Group type: COMPARATOR
Intervention: Experimental alcoholization study (9 subjects)
Number of subjects: 18
Study 31573666 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical skin formulation PT1 (2 strains of C. acnes SLST type C3 and K8, 50% each)
Number of subjects: 14
Study 31573666 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical skin formulation PT2 (4 strains of C. acnes SLST type C3 [55%], K8 [5%], A5 [30%] and F4 [10%])
Number of subjects: 14
Study 31573666 — intervention group
Group type: COMPARATOR
Intervention: 5% benzoyl peroxide gel (active induction phase, 7 days)
Number of subjects: 14
Study 27550732 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine (LDX)
Number of subjects: 14
Study 27550732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 25218370 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 STR and 1 ART
Number of subjects: 21
Study 25218370 — intervention group
Group type: COMPARATOR
Intervention: 2 STRs
Number of subjects: 21
Study 25218370 — intervention group
Group type: COMPARATOR
Intervention: 2 ARTs
Number of subjects: 21
Study 22688258 — intervention group
Group type: EXPERIMENTAL
Intervention: 25mg hydrocortisone
Number of subjects: 37
Study 22688258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 22068184 — intervention group
Group type: EXPERIMENTAL
Intervention: Polished surfaces (test group)
Number of subjects: 76
Study 22068184 — intervention group
Group type: COMPARATOR
Intervention: Unpolished surfaces (control group)
Number of subjects: 76
Study 19748761 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus NMES for four weeks (daily stimulation to both thighs for up to 30 minutes, frequency 50Hz, 'on' cycle 11%-25%)
Number of subjects: 16
Study 19748761 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus NMES for four weeks
Number of subjects: 16
Study 19748761 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 16
Study 17013637 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (B/N) 8/2 mg
Number of subjects: 8
Study 17013637 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (B/N) 16/4 mg
Number of subjects: 8
Study 17013637 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (B/N) 32/8 mg
Number of subjects: 8
Study 17013637 — intervention group
Group type: COMPARATOR
Intervention: Placebo (double-blind)
Number of subjects: 8
Study 15232046 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (12 weekly sessions)
Number of subjects: 17
Study 11371692 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (300 mg twice daily from 36‐38 weeks' gestation, 600 mg during labour, and 300 mg twice daily for 7 days post‐partum)
Number of subjects: 407
Study 11371692 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo)
Number of subjects: 407
Study 11371692 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 407
Study 11371692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 407
Study 11371692 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal CD4 lymphocyte count < 200/mm3
Number of subjects: 407
Study 11371692 — intervention group
Group type: EXPERIMENTAL
Intervention: Child HIV‐1 infection
Number of subjects: 407
Study 11371692 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal death
Number of subjects: 407
Study 11371692 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of paediatric infection on or before day 12
Number of subjects: 407
Study 11371692 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of paediatric infection between days 13 and 45
Number of subjects: 407
Study 11371692 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical paediatric AIDS
Number of subjects: 407
Study 9158849 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized single food meal
Number of subjects: 26
Study 9158849 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized mixed food meal
Number of subjects: 26
Study 9158849 — intervention group
Group type: COMPARATOR
Intervention: Matched non-hyperphagic controls with dementia
Number of subjects: 26
Study 9158849 — intervention group
Group type: COMPARATOR
Intervention: Matched normal elderly
Number of subjects: 26
Study 7963189 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment group
Number of subjects: 267
Study 7963189 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment group
Number of subjects: 267
Study 3524797 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose methotrexate (IDM)
Number of subjects: 634
Study 3524797 — intervention group
Group type: COMPARATOR
Intervention: Cranial irradiation (CRT) plus intrathecal methotrexate (MTX)
Number of subjects: 634
Study 31629306 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g of amino acid mixture twice daily for 7 days
Number of subjects: 94
Study 31629306 — intervention group
Group type: COMPARATOR
Intervention: Control group (no amino acid supplementation)
Number of subjects: 94
Study 29141739 — intervention group
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine (2.7 × 10^5 PfSPZ)
Number of subjects: 30
Study 29141739 — intervention group
Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 30
Study 27307526 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dosage MTX (7.5 mg/week)
Number of subjects: 309
Study 27307526 — intervention group
Group type: COMPARATOR
Intervention: High dosage MTX (20 mg/week)
Number of subjects: 309
Study 25491622 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous blood purification in combination with ulinastatin
Number of subjects: 40
Study 25491622 — intervention group
Group type: COMPARATOR
Intervention: Control group treatment (oxygen inhalation, dynamic ECG monitoring, physical cooling methods)
Number of subjects: 40
Study 23025303 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-generated arguments about exercise
Number of subjects: 183
Study 23025303 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-generated arguments about smoking cessation
Number of subjects: 183
Study 20307600 — intervention group
Group type: EXPERIMENTAL
Intervention: Craving condition (participants abstained from eating chocolate for 24h prior to testing)
Number of subjects: 96
Study 20307600 — intervention group
Group type: COMPARATOR
Intervention: Control condition (participants did not abstain from chocolate)
Number of subjects: 96
Study 18650153 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixabepilone 40 mg/m2 plus capecitabine 1650-2000 mg/m2 (schedule A)
Number of subjects: 106
Study 18650153 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixabepilone 8-10 mg/m2 plus capecitabine 1650 mg/m2 (schedule B)
Number of subjects: 106
Study 18650153 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixabepilone plus capecitabine (phase II)
Number of subjects: 106
Study 18650153 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 3/4 treatment-related events in phase II
Number of subjects: 106
Study 18650153 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 3/4 neutropenia and leukopenia
Number of subjects: 106
Study 16882128 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ibandronate 6 mg
Number of subjects: 0
Study 16882128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12514275 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (24 mg/d from an algal source)
Number of subjects: 36
Study 12514275 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotenoid mix (24 mg/d consisting of beta-carotene, lutein, and lycopene at 8 mg/d each)
Number of subjects: 36
Study 12514275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 10885881 — intervention group
Group type: EXPERIMENTAL
Intervention: Nickel exposure in mining sector
Number of subjects: 0
Study 10885881 — intervention group
Group type: EXPERIMENTAL
Intervention: Nickel exposure in smelting sector
Number of subjects: 0
Study 10885881 — intervention group
Group type: EXPERIMENTAL
Intervention: Nickel exposure in refining sector
Number of subjects: 0
Study 10885881 — intervention group
Group type: EXPERIMENTAL
Intervention: Nickel exposure in milling sector
Number of subjects: 0
Study 10885881 — intervention group
Group type: EXPERIMENTAL
Intervention: Median rate of change in exposure levels
Number of subjects: 0
Study 10885881 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplaces with no ventilation system
Number of subjects: 0
Study 10885881 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups of workers performing similar tasks
Number of subjects: 0
Study 10885881 — intervention group
Group type: EXPERIMENTAL
Intervention: North American workplaces
Number of subjects: 0
Study 8622025 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxol (paclitaxel) at a starting dose of 170 mg/m2 (135 mg/m2 for patients with prior pelvic radiation), given as a 24-hour continuous intravenous infusion every 3 weeks; dose adjustments allowed (escalations to 200 mg/m2 and deescalations to 110 mg/m2).
Number of subjects: 52
Study 1496731 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.1-[NANP]19 vaccine (50 or 400 micrograms doses)
Number of subjects: 13
Study 1496731 — intervention group
Group type: COMPARATOR
Intervention: Challenge with mosquitoes infected with P. falciparum
Number of subjects: 13
Study 2988774 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperazinedione (PZD)
Number of subjects: 127
Study 2988774 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoshi-864
Number of subjects: 127
Study 2988774 — intervention group
Group type: EXPERIMENTAL
Intervention: Razoxane (ICRF-159)
Number of subjects: 127
Study 2988774 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomustine (CCNU)
Number of subjects: 127
Study 2988774 — intervention group
Group type: EXPERIMENTAL
Intervention: ICRF-159 (in previously untreated patients)
Number of subjects: 127
Study 30063397 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-kV virtual monoenergetic imaging
Number of subjects: 209
Study 30063397 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine overlay imaging
Number of subjects: 209
Study 30063397 — intervention group
Group type: EXPERIMENTAL
Intervention: 120-kV simulated imaging
Number of subjects: 209
Study 27334739 — intervention group
Group type: EXPERIMENTAL
Intervention: UMEC 62.5 mcg added to ICS/LABA
Number of subjects: 236
Study 27334739 — intervention group
Group type: COMPARATOR
Intervention: PBO added to ICS/LABA
Number of subjects: 236
Study 22712527 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 8
Study 22712527 — intervention group
Group type: COMPARATOR
Intervention: Control exercise
Number of subjects: 8
Study 22321218 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplanted patients
Number of subjects: 20
Study 22321218 — intervention group
Group type: COMPARATOR
Intervention: Healthy children
Number of subjects: 20
Study 20638515 — intervention group
Group type: EXPERIMENTAL
Intervention: Open appendectomy
Number of subjects: 255
Study 20638515 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 255
Study 20638515 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined open and laparoscopic patients
Number of subjects: 255
Study 20638515 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordant complicated appendicitis
Number of subjects: 255
Study 20638515 — intervention group
Group type: EXPERIMENTAL
Intervention: Discordant complicated appendicitis
Number of subjects: 255
Study 18381467 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report of colonoscopy (COL)
Number of subjects: 857
Study 18381467 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report of fecal occult blood test (FOBT)
Number of subjects: 857
Study 18381467 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report of sigmoidoscopy (SIG)
Number of subjects: 857
Study 18381467 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report of barium enema (BE)
Number of subjects: 857
Study 17660155 — intervention group
Group type: EXPERIMENTAL
Intervention: Splint (exercises given 3 weeks postoperatively)
Number of subjects: 40
Study 17660155 — intervention group
Group type: COMPARATOR
Intervention: Bulky bandage (exercises provided immediately)
Number of subjects: 40
Study 15384889 — intervention group
Group type: EXPERIMENTAL
Intervention: Food inducing anti-secretory factor (AF)
Number of subjects: 40
Study 15384889 — intervention group
Group type: COMPARATOR
Intervention: Control group food without AF-inducing properties
Number of subjects: 40
Study 15384889 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 40
Study 15384889 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers with mastitis (experimental group)
Number of subjects: 40
Study 15384889 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers without mastitis (experimental group)
Number of subjects: 40
Study 11274092 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency-Doubling Perimetry (FDP)
Number of subjects: 60
Study 11274092 — intervention group
Group type: COMPARATOR
Intervention: Humphrey Field Analyzer (HFA)
Number of subjects: 60
Study 11274092 — intervention group
Group type: EXPERIMENTAL
Intervention: Test durations for FDP
Number of subjects: 60
Study 11274092 — intervention group
Group type: COMPARATOR
Intervention: Test durations for HFA
Number of subjects: 60
Study 9412308 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 1829
Study 12959271 — intervention group
Group type: EXPERIMENTAL
Intervention: Remikiren 200 mg
Number of subjects: 144
Study 12959271 — intervention group
Group type: EXPERIMENTAL
Intervention: Remikiren 300 mg
Number of subjects: 144
Study 12959271 — intervention group
Group type: EXPERIMENTAL
Intervention: Remikiren 600 mg
Number of subjects: 144
Study 12959271 — intervention group
Group type: EXPERIMENTAL
Intervention: Remikiren 800 mg
Number of subjects: 144
Study 12959271 — intervention group
Group type: COMPARATOR
Intervention: Remikiren (various doses)
Number of subjects: 144
Study 12959271 — intervention group
Group type: EXPERIMENTAL
Intervention: Remikiren
Number of subjects: 144
Study 2882766 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 0.5, 1.0 and 1.5 mg kg‐1 in an elixir formulation
Number of subjects: 220
Study 2882766 — intervention group
Group type: COMPARATOR
Intervention: Trimeprazine tartrate 3 mg kg‐1 in a syrup
Number of subjects: 220
Study 31464933 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture in combination with prokinetic drugs
Number of subjects: 28
Study 31464933 — intervention group
Group type: COMPARATOR
Intervention: Routine ICU treatment (Control)
Number of subjects: 28
Study 28669169 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage III breast cancer at diagnosis
Number of subjects: 600
Study 28669169 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural residence
Number of subjects: 600
Study 28669169 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, tumor size, tumor grade at diagnosis, hormone receptor status of estrogen and progesterone, Her-2
Number of subjects: 600
Study 26860019 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg intravenous 10 min before surgery)
Number of subjects: 60
Study 26860019 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline equivalent volume 30 min before surgery)
Number of subjects: 60
Study 23334615 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 15
Study 23334615 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 15
Study 21732218 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (0.625 mg/day of conjugated equine estrogens)
Number of subjects: 59
Study 21732218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 19660039 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic information based on baseline wound characteristics
Number of subjects: 0